290 related articles for article (PubMed ID: 27663393)
1. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.
Dickinson L; Ahmed HU; Hindley RG; McCartan N; Freeman A; Allen C; Emberton M; Kirkham AP
Urol Oncol; 2017 Jan; 35(1):30.e9-30.e15. PubMed ID: 27663393
[TBL] [Abstract][Full Text] [Related]
2. Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease.
Punwani S; Emberton M; Walkden M; Sohaib A; Freeman A; Ahmed H; Allen C; Kirkham A
Br J Radiol; 2012 Jun; 85(1014):720-8. PubMed ID: 22253342
[TBL] [Abstract][Full Text] [Related]
3. Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer.
Rosenhammer B; Niessen C; Rotzinger L; Reiss J; Schnabel MJ; Burger M; Bründl J
Urol Int; 2019; 103(3):270-278. PubMed ID: 31466073
[TBL] [Abstract][Full Text] [Related]
4. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
Huber PM; Afzal N; Arya M; Boxler S; Dudderidge T; Emberton M; Guillaumier S; Hindley RG; Hosking-Jervis F; Leemann L; Lewi H; McCartan N; Moore CM; Nigam R; Odgen C; Persad R; Thalmann GN; Virdi J; Winkler M; Ahmed HU
J Urol; 2020 Apr; 203(4):734-742. PubMed ID: 31928408
[TBL] [Abstract][Full Text] [Related]
5. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer.
Khandwala YS; Soerensen SJC; Morisetty S; Ghanouni P; Fan RE; Vesal S; Rusu M; Sonn GA
Eur Urol Focus; 2023 Jul; 9(4):584-591. PubMed ID: 36372735
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation.
Khandwala YS; Morisetty S; Ghanouni P; Fan RE; Soerensen SJC; Rusu M; Sonn GA
Urol Oncol; 2022 Nov; 40(11):489.e9-489.e17. PubMed ID: 36058811
[TBL] [Abstract][Full Text] [Related]
7. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
8. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1.
Apfelbeck M; Clevert DA; Ricke J; Stief C; Schlenker B
Clin Hemorheol Microcirc; 2018; 69(1-2):93-100. PubMed ID: 29660918
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.
von Hardenberg J; Westhoff N; Baumunk D; Hausmann D; Martini T; Marx A; Porubsky S; Schostak M; Michel MS; Ritter M
Urol Oncol; 2018 Sep; 36(9):401.e1-401.e9. PubMed ID: 30093211
[TBL] [Abstract][Full Text] [Related]
10. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer?
Abd-Alazeez M; Ahmed HU; Arya M; Charman SC; Anastasiadis E; Freeman A; Emberton M; Kirkham A
Urol Oncol; 2014 Jan; 32(1):45.e17-22. PubMed ID: 24055430
[TBL] [Abstract][Full Text] [Related]
11. Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
Rompré-Brodeur A; Marcq G; Tholomier C; Fugaru I; Loutochin O; Anidjar M; Bladou F
J Urol; 2021 Nov; 206(5):1177-1183. PubMed ID: 34251879
[TBL] [Abstract][Full Text] [Related]
12. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
13. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
15. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
16. [The correlation of PSA-nadir PS recurrence after total HIFU-ablation in patients with localized prostate cancer].
Fomkin RN; Krupinov GE; Churakov AA; Shatylko TV; Fomkina OA; Zhmakin VA
Urologiia; 2020 Sep; (4):79-83. PubMed ID: 32897659
[TBL] [Abstract][Full Text] [Related]
17. Focal high-intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study.
Ladjevardi S; Ebner A; Femic A; Huebner NA; Shariat SF; Kraler S; Kubik-Huch RA; Ahlman RC; Häggman M; Hefermehl LJ
Eur J Clin Invest; 2024 Jun; 54(6):e14192. PubMed ID: 38445798
[TBL] [Abstract][Full Text] [Related]
18. PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure.
Shah TT; Peters M; Kanthabalan A; McCartan N; Fatola Y; van der Voort van Zyp J; van Vulpen M; Freeman A; Moore CM; Arya M; Emberton M; Ahmed HU
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):311-6. PubMed ID: 27431499
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.
MacAskill F; Lee SM; Eldred-Evans D; Wulaningsih W; Popert R; Wolfe K; Van Hemelrijck M; Rottenberg G; Liyanage SH; Acher P
Int Urol Nephrol; 2017 Aug; 49(8):1335-1342. PubMed ID: 28477301
[TBL] [Abstract][Full Text] [Related]
20. High-intensity Focused Ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response.
Dason S; Wong NC; Allard CB; Hoogenes J; Orovan W; Shayegan B
Int Braz J Urol; 2018; 44(2):248-257. PubMed ID: 29211405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
